EULAR 2019 - Day 1 Report
Here are a few of the highlights from day 1 EULAR in Madrid.
News
Industry Press Releases from EULAR19
Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Preview of EULAR 2019 Abstracts
EULAR 2019 begins today in Madrid and features over 2000 presentations. After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.
Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells. HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.
Updated 2018 EULAR Recommendations for the Diagnosis of Gout
The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.
Excess Non-CV Mortality Persists in Gout
Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.
ACR Supports Legislation to Improve Oversight and Transparency of Prior Authorization Use
Rheumatology Leaders Join a Coalition of National Medical Specialties in Urging Congress to Protect Patients from Prior Authorization Requirements in Medicare Advantage Plans
RheumNow Podcast – Drug Ad Transparency (6.7.19)
Dr. Jack Cush reviews the news and journal articles of note from this past week on RheumNow.com.
More Trouble for Mallinckrodt’s Acthar Gel
Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.
FDA Public Review of CBD Oil
The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.
